CV
Chelakkara Vaidyanathan Sriram
About Chelakkara Vaidyanathan Sriram
Data last updated:
Chelakkara Vaidyanathan Sriram is a Managing Director at Baryton Pharma Private Limited (since 2010) and Designated Partner at Baryton Enterprises Llp (since 2024). The companies operate in Pharma. The largest current company by reported revenue is Baryton Pharma Private Limited at ₹13.67 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Baryton Pharma Private Limited U24232KL2010PTC026716 | Managing Director | 17 Sep 2010 | 2010 | ₹13.67 Cr (FY 2025) | Active |
 Baryton Enterprises Llp ACK-2705 | Designated Partner | 08 Nov 2024 | 2024 | Active |
Board colleagues of Chelakkara Vaidyanathan Sriram
| Name | DIN | Company | Designation |
|---|---|---|---|
| Praveen Viswakumar | 03246721 | Baryton Pharma Private Limited , Baryton Enterprises Llp | Director |
| Ranjish Rayaroth | 03196169 | Baryton Pharma Private Limited , Baryton Enterprises Llp | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Chelakkara Vaidyanathan Sriram
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chelakkara Vaidyanathan Sriram
Chelakkara Vaidyanathan Sriram currently holds 2 directorships: Baryton Pharma Private Limited (Managing Director, since 17 Sep 2010, revenue ₹13.67 Cr (FY 2025)); Baryton Enterprises Llp (Designated Partner, since 08 Nov 2024).
Chelakkara Vaidyanathan Sriram was first appointed on 17 Sep 2010 as Managing Director at Baryton Pharma Private Limited. The most recent appointment on record is 08 Nov 2024 at Baryton Enterprises Llp.
The current boards of Chelakkara Vaidyanathan Sriram's companies include Praveen Viswakumar (Baryton Pharma Private Limited), Ranjish Rayaroth (Baryton Pharma Private Limited).